John E. Milad
CEO & Founder
John is CEO of Quanta Dialysis Technologies, where he was both a founding board member and an original investor through NBGI Ventures. He had the belief and vision that the initial technology concept of a novel fluid management system could be transformed into a disruptive medical product addressing the unmet needs of the $73 billion global dialysis market by using innovation to empower patients and deliver better outcomes.
John’s career spans more than twenty years, with extensive international experience in building and growing successful healthcare companies as an executive manager, board member, private equity investor and corporate financier. He is currently an Advisory Board member of Digital Health Forum and is a regular speaker and panellist at global medtech and investment conferences. Prior to his role as CEO of Quanta, John was Investment Director at NBGI Ventures, where he was closely involved with a range of innovative medical technology companies in Europe and the US, both as a board member and an investor. John has also held senior positions at Nitec Pharma AG (now Horizon Pharma plc), Atlas Venture and Nomura international and previously served as a member of the i4i selection panel at the NHS National Institute for Health Research. John has also served on the Board of Directors at Cellnovo Ltd, Symetis SA, BoneSupport AB and Advanced Cardiac Therapeutics Inc. He holds a BA in Political Science from The University of Chicago.
Chief Financial Officer
Willem has almost twenty years of investment banking, executive management, and private equity experience. Amongst his achievements, he was pivotal in the $1.6bn turnaround and public listing of FLAG Telecom and was co-founder and CFO of Arqaam Capital, one of the largest boutique investment banks based in Dubai. Previously, he has worked at the telecommunications firm Ameritech (SBC), as well the investment banks Deutsche Bank and Panmure Gordon. More recently, he led the acquisition and the subsequent merger of the real-estate agency Humberts with Chesterton. As Deputy Chairman of the enlarged Chesterton Humberts he oversaw its growth into one of the largest real-estate agencies in the UK.
Willem has undergraduate degrees in business administration and computer science from Lehigh University and an MBA from Kellogg Graduate School of Business.
Chief Commercial Officer
Peter has more than 25 years of experience in the medical device industry and started his professional career with Fresenius AG in Germany, later working at Fresenius Medical Care in Asia Pacific as regional Marketing Director for the dialysis products business. He moved on to work as the Marketing Manager for Amgen GmbH in Munich, Germany, where he was in charge of the launch of Aranesp® (Erythropoietin; darbepoetin alfa).
Prior to joining Quanta, Peter established and managed the DJO/Aircast regional offices in Hong Kong. Peter has a clinical background and holds an MBA in Strategic Marketing from the University of Hull as well as an EMBA in International Marketing from the KS Graduate Business School St. Gallen, Switzerland.
Chief Technology Officer
Clive was part of the founding team that initially developed the concept of Quanta's SC+ system and obtained initial venture funding.
Previously, Clive worked for the BMW group with responsibility for the vehicle physics department. In 2001, he became an honorary professor within the Department of Engineering and Physics at Heriot-Watt University and in 2011 was elected a Fellow of the Royal Academy of Engineering and a Fellow of the Institute of Physics. Most recently, in 2018, Clive was accepted as a committee member of the IEC standards setting body for dialysis systems (60601-2-16).
Chief of Operations
Rolf has 25 years of experience in purchasing, supply chain and operations within the pharmaceuticals and medical device industries. Before joining Quanta, Rolf held the position of Director Supply Chain, Outsourced Manufacturing and Facility Management at Biocartis, where he was responsible for the outsourced manufacturing activities and led the selection and contracting process for outsourcing and implementation of supply chain and logistics processes to support product launch. Previously, Rolf has held various senior leadership roles with Merck Animal Health, Intervet Schering Plough Animal Health and Intervet International. Rolf has a Bachelors Degree in Economics from the University of Applied Sciences in Arnhem, Netherlands.
Interim Chief of Quality and RA
Mike has over 30 years’ experience with medical device and pharmaceutical companies both in Quality and Regulatory Affairs. He has worked with
Class I – IIb medical device products in applications ranging from contact lenses, laryngoscopy, thrombin-fibrinogen delivery, ultrasonic measurement and analgesic combination product systems.
Prior to joining Quanta, Mike has held senior operational positions at CooperVision, the world’s 3rd largest manufacturer of contact lenses, Verathon Medical, Hospira, Johnson & Johnson, Pfizer and Bristol-Myers Squibb.
Mike holds a PhD in Chemistry and an MBA from University College Dublin and is a certified ISO13485 Lead Auditor. He is a member of ABHI’s Technical Policy and MDR Implementation Working Groups.
Amit is a technical leader with a strong background in complex systems engineering, having successfully launched multiple mission-critical systems for medical devices, life sciences and other applications. He has a passion for innovation and a proven track-record of building, motivating and energising product development teams. Amit joined Quanta in 2016 from a position of Head of Engineering at Biocartis, where he helped launch their flagship product in molecular diagnostics and was part of the leadership team that took the company to IPO. He has also previously held various engineering leadership roles at Life Technologies, Luminous Medical and Covidien. Amit has a Masters in Biomedical Engineering from the University of Minnesota, Twin Cities, USA and a Bachelor’s in Electrical Engineering from Sivaji University in India.